Protego Biopharma closed a $130 million financing to support a potential pivotal study of its oral small molecule for light chain (AL) amyloidosis. Investors behind the round include executives and backers associated with Vyndaqel, reflecting confidence in Protego’s protein‑stabilizing mechanism after recent failures of antibody approaches. Protego says the drug stabilizes misfolded light‑chain proteins and could offer an alternative to antibody-based strategies from AstraZeneca and Prothena that failed in pivotal tests earlier this year. The financing is earmarked to enable a pivotal trial next year and commercial-readiness activities if the program succeeds.